HAYWARD, Calif., July 18, 2000 (PRIMEZONE) -- Questcor Pharmaceuticals, Inc. (AMEX:QSC), a fully integrated specialty pharmaceutical company focusing on serving the acute care and critical care hospital markets, announced today that its CEO, Charles J. Casamento, will be making a formal presentation to analysts, money managers, investment bankers and investors expected to attend the Informed Investors Ninth Bay Area Biotechnology Stocks Forum on Saturday, July 22nd, either onsite at the Hilton San Francisco at 333 O'Farrell Street or live on the Internet through Yahoo! Broadcast Services (www.broadcast.com). To register please call 1-800-992-4683.
The conference day, which will feature 15 leaders from emerging NASDAQ and AMEX biotech companies, is organized by InformedInvestors.com, the leading channel to retail investors. Questcor will be one of the local exhibitors at the conference. Mr.Charles J. Casamento, Questcor's CEO, will be making a formal presentation at 2:15 PM. He will also be available for private meetings with analysts, portfolio managers, media and other members of the investment community later that day. In addition, the event will include a keynote address by be Ken Kam, the co-fund manager for the Technology Value Fund, and manager, Medical Specialists Fund.
"The Informed Investors Bay Area Forum is an excellent venue to report Questcor's progress and achievements to hundreds of financial industry professionals and institutional investors, including our local shareholders. We are exited to join the elite emerging biotech companies at this premier event," said Mr. Casamento.
Questcor Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company whose focus is to serve the needs of the acute care and critical care hospital market. The Company's strategy includes the acquisition and marketing of hospital pharmaceutical products, the generation of revenue streams from these products and the continued funding of late stage, acute care and critical care pharmaceutical research and development programs. Questcor was created as a result of the merger, on November 17, 1999, between Cypros Pharmaceutical Corp. and RiboGene, Inc.
For more information on Questcor, please contact the company's website at www.Questcor.com.
Note: Except for the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties. Such statements are subject to certain factors, which may cause the Company's results to differ. Factors that may cause such differences include, but are not limited to, the Company's need for additional funding, uncertainties regarding the company's intellectual property and other research, development, marketing and regulatory risks, and, the ability of the Company to implement its strategy and acquire products and, if acquired, to market them successfully as well as the risks discussed in Questcor's transition report on Form 10-K for the fiscal year ended December 31, 1999 and the Risk Factor section of Cypros' Registration Statement on form S-4 (No. 333-87611), RiboGene's Annual Report on Form 10-K for the fiscal year ended December 31, 1998 and other documents filed with the Securities and Exchange Commission. The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance.